Key Drivers
- Margin Strength
- Liquidity Cushion
- Profitability Gap
AIAI Summary
SUPN now looks less like a struggling specialty pharma and more like a cash-generative growth story with real commercial traction, but the stock only works if management sustains Q1's momentum in Qelbree/GOCOVRI/ONAPGO and converts that revenue into margins because valuation already assumes continued execution.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Strength
- •Liquidity Cushion
- •Profitability Gap
SUPN has strong margins, solid liquidity and free cash flow, and modest leverage, but persistent losses and a demanding valuation keep it a cautious hold.
Price Behavior
Key Price Behavior Insights:
- •Range-bound action
- •Firm $48 support
- •Failed bounce
SUPN is still range-bound and mildly soft, with support near $47.85-$48.00 and resistance around $51.2-$52.3, so a sustained move back above $51.5 is needed to improve the technical picture.
Sharp rebound to $52.28 on 2026-05-07, but the early-May bounce failed to hold
Sentiment & News
Key News Insights:
- •Q1 Beat
- •Investor Outreach
- •Fund Sale
Supernus posted a strong Q1 2026 beat on both EPS and revenue while continuing active investor engagement, though a later fund sale added a modest cautionary note.
The earnings outperformance and ongoing management visibility are supportive for sentiment, but the stock may see some near-term caution after the reported profit-taking
Similar Companies in Healthcare
Other companies in the same sector with AI ratings